Unjha Formulations Ltd Downgraded to Strong Sell Amid Technical and Financial Weakness

Quality Assessment: Weakening Fundamentals and Debt Concerns

Unjha Formulations’ quality rating has come under pressure due to its flat financial performance in the third quarter of FY25-26 and a lacklustre long-term growth trajectory. The company has recorded a modest 15.77% compound annual growth rate (CAGR) in operating profits over the past five years, which is below industry expectations for pharmaceuticals and biotechnology firms. More concerning is the company’s poor ability to service its debt, with an average EBIT to interest coverage ratio of just 0.54, signalling significant financial strain and heightened risk for creditors and investors alike.

Despite a robust return on equity (ROE) of 33.1%, which typically indicates efficient capital utilisation, the overall quality grade has been dragged down by these operational and financial weaknesses. The majority of shareholders remain non-institutional, which may limit the availability of strategic support or capital infusion during challenging periods.

Valuation: Attractive on Price-to-Book but Clouded by Performance

From a valuation standpoint, Unjha Formulations presents a mixed picture. The stock trades at a price-to-book (P/B) ratio of 2.9, which is considered very attractive relative to its peers in the pharmaceuticals sector. This discount to historical valuations could appeal to value investors seeking entry points in beaten-down stocks. Additionally, the company’s price-earnings-to-growth (PEG) ratio stands at a low 0.1, reflecting a disconnect between its rising profits—up 41% over the past year—and the declining share price.

However, the valuation appeal is tempered by the stock’s recent underperformance. Over the last year, Unjha Formulations has delivered a negative return of -19.96%, significantly lagging the BSE500 benchmark’s -8.66% return. This underperformance extends to the three-year horizon as well, where the stock’s 43.65% gain trails the Sensex’s 27.50% rise, indicating that despite some long-term gains, the company has struggled to maintain momentum in recent periods.

Financial Trend: Flat Quarterly Results and Weak Profitability Trajectory

The company’s financial trend has been largely flat in the near term, with Q3 FY25-26 results showing no significant growth. This stagnation contrasts with the 41% profit increase over the past year, suggesting volatility and inconsistency in earnings. The weak EBIT to interest ratio further highlights the company’s struggle to generate sufficient operating income to cover its debt obligations, raising concerns about financial sustainability.

Long-term returns also paint a challenging picture. While Unjha Formulations has outperformed the Sensex over five years with a 147.34% gain versus 58.20%, the recent one-year and year-to-date returns of -19.96% are well below market averages. This divergence indicates that the company’s growth momentum has slowed considerably, impacting investor confidence and prompting a reassessment of its financial outlook.

Technicals: Downgrade to Bearish Amid Multiple Negative Indicators

The most significant trigger for the downgrade to a Strong Sell rating is the deterioration in technical indicators. The technical trend has shifted from mildly bearish to outright bearish, reflecting increasing selling pressure and weakening momentum. Key technical signals include:

• MACD (Moving Average Convergence Divergence): Weekly readings remain mildly bullish, but monthly MACD has turned mildly bearish, indicating a loss of upward momentum over the longer term.
• RSI (Relative Strength Index): Both weekly and monthly RSI show no clear signal, suggesting indecision but no immediate bullish reversal.
• Bollinger Bands: Both weekly and monthly bands are bearish, signalling increased volatility and downward price pressure.
• Moving Averages: Daily moving averages are firmly bearish, confirming short-term weakness.
• KST (Know Sure Thing): Both weekly and monthly KST indicators are bearish, reinforcing the negative trend.
• Dow Theory: No clear trend is identified on weekly or monthly charts, indicating a lack of directional conviction.

These technical factors have contributed to a sharp decline in the stock price, which closed at ₹20.01 on 7 May 2026, down 6.84% from the previous close of ₹21.48. The stock’s 52-week high stands at ₹30.40, while the low is ₹18.60, highlighting the recent downward pressure. The one-week return of -9.05% starkly contrasts with the Sensex’s 1.21% gain, underscoring the stock’s relative weakness.

Contextualising the Downgrade: Micro-Cap Risks and Sector Challenges

Unjha Formulations operates within the Pharmaceuticals & Biotechnology sector, a space characterised by rapid innovation but also intense competition and regulatory scrutiny. As a micro-cap company, it faces additional challenges including limited liquidity, higher volatility, and less institutional investor support. These factors amplify the impact of weak financial and technical signals on investor sentiment.

While the company’s valuation metrics suggest some appeal, the combination of flat recent financial results, poor debt coverage, and deteriorating technical indicators has led to a comprehensive downgrade in its investment rating. The MarketsMOJO Mojo Score now stands at 26.0, with a Mojo Grade of Strong Sell, down from a previous Sell rating. This reflects a consensus view that the stock currently carries elevated risk and limited upside potential.

Investor Takeaway: Caution Advised Amid Mixed Signals

Investors should approach Unjha Formulations with caution given the current rating downgrade. The stock’s attractive valuation metrics are offset by weak financial trends and bearish technical signals. The company’s inability to consistently grow profits and service debt raises concerns about its operational resilience. Furthermore, the recent sharp price decline and underperformance relative to benchmarks suggest that market sentiment remains negative.

For those considering exposure to the pharmaceuticals sector, it may be prudent to explore alternatives with stronger fundamentals and more favourable technical momentum. The downgrade to Strong Sell signals that Unjha Formulations is currently not a preferred choice for risk-averse or growth-oriented investors.

Summary of Ratings and Scores:

• Mojo Score: 26.0 (Strong Sell)
• Previous Grade: Sell
• Market Cap Grade: Micro-cap
• Technical Trend: Downgraded from mildly bearish to bearish
• Financial Trend: Flat quarterly results, weak EBIT to interest ratio (0.54)
• Valuation: Attractive P/B of 2.9, PEG ratio 0.1, but offset by negative returns
• Quality: Weak long-term growth, poor debt servicing, ROE 33.1

Overall, the downgrade reflects a comprehensive reassessment of Unjha Formulations’ investment profile, driven primarily by deteriorating technicals and financial trends despite some valuation appeal.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →